Veraxa Biotech is trading 5.3% down now at $1.14, based on the provided pre-market price context; the cause is unclear. - No verified announcement on October 14 explains the move. - On October 13, the company reported early proof-of-concept findings for its BiTAC-ADC platform, including tumor regression in a breast cancer model; the release did not link the findings to the share-price move. - Major U.S. indices were slightly higher. Trading volume or activity details were not provided.